Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

Main Article Content

Jonathan Silverberg
Andrew Pink
Christina Olsen
Stephan Weidinger

Keywords

Atopic Dermatitis, Tralokinumab, Topical Corticosteroids

Abstract

Abstract not available.

References

1. Nutten S. Ann Nutr Metab 2015; 66(Suppl 1): 8–16.

2. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

3. Eckert L et al. J Am Acad Dermatol 2017; 77: 274–279.e273.

4. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

5. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

6. Bieber T. Allergy 2020; 75: 54–62.

7. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

8. Eichenfield LF et al. J Am Acad Dermatol 2014; 71: 116–132.

9. Boguniewicz M et al. J Allergy Clin Immunol Pract 2017; 5: 1519–1531.

10. Popovic B et al. J Mol Biol 2017; 429: 208–219.

11. Weidinger S et al. Oral presentation at the American Academy of Dermatology Virtual Meeting,
2020.

12. Choi JY et al. Br J Dermatol 2020; 182: 1017–25.